SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

SYMTUZA

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed, US FDA approval July 17, 2018; no launch or approval risk remaining.
Why 3/10
No hard, dated binary catalyst in the next ~12 months: SYMTUZA was approved in July 2018 and is a mature marketed product whose only recent FDA event was a routine safety-labeling update (April 2026), an approved drug with no pending PDUFA/pivotal readout scores 3-5 per the rubric, and at the low end because it is one small product inside a mega-cap whose stock thesis is driven by oncology/immunology.
Actionable Insight NEUTRAL

For JNJ shareholders, Symtuza is not a stock-moving catalyst, it is a mature, marketed HIV drug with no dated binary in the next year, so there is nothing to trade on the drug itself. Investors seeking HIV single-tablet-regimen exposure with actual catalysts should look to the pure-play HIV names (Gilead, ViiV) rather than JNJ; for JNJ, treat Symtuza as steady-state revenue and monitor quarterly earnings for HIV-franchise trends.

Price Chart

Loading chart...

Executive Summary

SYMTUZA is Johnson & Johnson's (Janssen) four-drug, once-daily single-tablet HIV regimen, approved by the FDA on July 17, 2018 as the "first and only complete darunavir-based single-tablet regimen" for HIV-1, later expanded to include pediatric patients. It is a fully marketed, mature product inside a mega-cap pharma whose value is dominated by oncology and immunology franchises, the drug is a stable but immaterial contributor to JNJ's share price, and the stock's modest +2.49% one-day move around its 2018 approval reflects that. There is no scheduled regulatory catalyst for SYMTUZA in the next 12 months; the notable recent event was an April 2026 FDA safety-labeling update on hepatitis B co-infection.

How It Works

One daily pill combining four anti-HIV medicines that attack the virus at different steps: darunavir stops HIV from assembling new copies of itself, cobicistat boosts darunavir's levels so it works harder, and emtricitabine plus tenofovir alafenamide block the virus's copying machinery. Bundling all four into a single tablet is designed to keep the virus suppressed while making it easier to take than several separate pills.

Trial Status

FDA-approved in the US on July 17, 2018 as a complete regimen for HIV-1 in treatment-naive and certain virologically suppressed adults; the Nov 2023 FDA label version covers pediatric patients weighing at least 40 kg; a safety-labeling update recorded April 2026 strengthened the hepatitis B (HBV) co-infection warning about severe acute HBV exacerbations after discontinuation.

The Two-Sided Case

▲ Bull Case4
First and only complete darunavir-based single-tablet regimen for HIV-1 at approval (J&J press release, PR Newswire, pharmaphorum), darunavir's high barrier to resistance differentiates it from integrase-based rivals for patients with resistance concerns.
Approved across the adult HIV-1 population (treatment-naive and virologically suppressed) and label expanded to pediatrics per the Nov 2023 FDA label.
Zero binary regulatory risk: already approved and marketed since 2018; the April 2026 FDA safety-labeling update is routine post-market monitoring, not an approval threat.
For JNJ holders, Symtuza carries no dilution or survival risk, it is one product in a $260+/share mega-cap with analyst consensus 'buy' (22 price targets, mean $272.50, high $305, low $190, as of Aug 2026).
▼ Bear Case4
The HIV single-tablet market is one of the most competitive in pharma, dominated by Gilead and ViiV regimens; Symtuza's protease-inhibitor franchise faces entrenched rivals on new prescriptions, no tool result quantified its market share, so treat share pressure as a qualitative risk.
April 2026 FDA safety-labeling action flags the risk of severe acute hepatitis B (HBV) exacerbations when HIV/HBV co-infected patients stop SYMTUZA, a prescribing-hurdle and liability consideration.
Symtuza is immaterial to JNJ's stock: no binary catalyst, no growth narrative, recent analyst target raises (TD Cowen to $300, Morgan Stanley to $294, Guggenheim to $287 in July-Aug 2026) are driven by the oncology/immunology pipeline, not HIV.
JNJ-level insider selling context: CEO Duato exercised options and sold ~$32.2M gross of stock on Aug 13, 2026 (Form 4 filings), not drug-specific but a general sentiment flag.

Upcoming Catalysts

  • None scheduled for SYMTUZA specifically in the next 12 months (no PDUFA date, no pivotal readout, no dated label-expansion decision).
  • Watch for further FDA safety communications or label changes following the April 2026 hepatitis B warning update.
  • JNJ quarterly earnings (next ~mid-October 2026) will show HIV-franchise sales trends, but these are not drug-specific binaries.
  • Longer-term: competitive dynamics and generic erosion in the HIV single-tablet market.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 10

Hover a chip for the title
1 jnj.com2 prnewswire.com3 biospace.com4 drugs.com5 fda.gov6 pharmaphorum.com7 drugs.com8 symtuza.com9 clinicalinfo.hiv.gov10 accessdata.fda.gov